Novo Nordisk Just Committed More Than $1.1 Billion to Make …
WEB2 days ago · In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D) costs, payments, milestone fees, and royalties, with the explicit...
Latest news - Novo Nordisk
WEBAug 6, 2024 · Latest news. 20 September 2024. Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed. Read more. 19 September 2024. Novo Nordisk A/S: Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function. Read more. 06 …
Inside Novo Nordisk, the Company Behind Ozempic and Wegovy …
WEBApr 20, 2024 · Novo Nordisk’s factories work nonstop turning out Ozempic and Wegovy, its blockbuster weight-loss drugs, but the Danish company has far bigger ambitions.
Company announcements and press releases - Novo Nordisk
WEBNovo Nordisk press releases and company announcements.
Novo Nordisk signs deals worth up to $1bn with US biotechs in …
WEBJan 4, 2024 · Novo Nordisk has signed deals worth up to $1bn with US biotech start-ups developing treatments for obesity and other cardiometabolic diseases, as the Wegovy manufacturer seeks to stay ahead in...
News Details - novonordisk.com
WEBSep 20, 2024 · Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist.
Novo Nordisk successfully completes phase 2 trial with
WEBBagsværd, Denmark, 22 August 2022 – Novo Nordisk today announced headline results from a phase 2 clinical trial with CagriSema, a once-weekly subcutaneous combination of semaglutide and a novel...
Novo Nordisk receives FDA approval for Wegovy™ to treat …
WEBPLAINSBORO, N.J., June 4, 2021 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the new drug application (NDA) for Wegovy ™ (semaglutide)...
Novo Nordisk strikes $11bn deal to expand production of weight …
WEBFeb 5, 2024 · Novo Nordisk has agreed to acquire three manufacturing sites for $11bn, as the Danish drugmaker races to expand production of the weight loss drugs whose runaway success has sent the company’s...
Novo Nordisk's CEO took the Washington hot seat over Ozempic …
WEB5 days ago · Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen agreed today, during a Senate committee hearing, to sit down with lawmakers and pharmacy benefit managers (PBMs) to look into the...
Skip to content